粒细胞—巨噬细胞集落刺激因子／白细胞介素—3融合蛋白的表达研究

利用ＰＣＲ扩增得到粒细胞－巨噬细胞集落刺激因子（ＧＭ－ＣＳＦ）、白细胞介素－３（ＩＬ－３）完整基因片段,将其分别克隆ｐＧＥＭ－Ｔ构建成ＧＭ－ＣＳＦ／ＩＬ－３融合蛋白基因,ＤＮＡ序列与设计预期一致。将得到的融合蛋白基因克隆对７２ＲＮＡ聚合酶表达载体ｐＴ７ｚｚ,得到表达质粒ｐＦｕ,经转化至表达宿主Ｅ．ｃｏｌｉ ＢＬ２１（ＤＥ３）,在ＩＰＴＧ诱导下获得融合蛋白目的产物的直接表达。经ＳＤＳ－ＰＡＧＥ电泳鉴     

蓝舌病病毒Z1株VP7基因的克隆及序列分析

用ＲＴ－ＰＣＲ扩增我国蓝舌病毒Ｚ１株的ＶＰ７基因,直接将其克隆至ｐＧＥＭ－Ｔ载体中,用限制性内切酶ＥｃｏＲＩ分析经蓝／白斑筛选和ＰＣＲ鉴定的重组质粒,用ＤＩＧ标记克隆片段制成探针与病毒基因组进行Ｎｏｒｔｈｅｒｎ ｂｌｏｔ杂交,证明插入片段为ＢＴＶ ＶＰ７基因特异性片段。采用Ｓａｎｇｅｒ双脱氧终止法测定ｃＤＮＡ片段的核苷酸序列,将这一序列与国外已发表的９株蓝舌病毒及相关的环状病毒的ＶＰ７基因进行了比     

LDL受体基因cDNA的RT—PCR分离,克隆及其在RFLP中的应用

利用ＲＴ－ＰＣＲ技术分离低密度脂蛋白受体基因ｃＤＮＡ,将长为２６０５ｂｐ的ｃＤＮＡ插入质粒ｐＪＮ６,并经全序列测定证实,该序列与已报道序列相比,存在两个变异碱基,即第７５４位Ｃ→Ｔ,和１６５４位的Ｇ→Ａ,这两个变异碱基并不改变编码的氨基酸,利用ＬＤＬ受体基因ｃＤＮＡ中的ＣｌａＩ片段的作为探针,检测到ＬＤＬ受体基因上外显子８的ＳｔｕＩ位点是个限制性片段长度多态性位点,所克隆的ｃＤＮＡ含有可译框架的全     

日本血吸虫(中国大陆株)谷胱甘肽转移酶编码区基因的体外扩增、克隆及在原核细胞的高效表达

为表达、获取日本血吸早谷胱甘肽转移酶（ＳｊＧＳＴ）基因工程重组蛋白,以日本血吸虫（中国大陆株）ｃＤＮＡ为模板,设计、合成特定寡核苷酸引物,ＲＴ－ＰＣＲ法扩增ＧＳＴ编码基因序列,将扩增产物连接ｐＧＥＭ－Ｔ克隆载体,再亚克隆到真、原核表达质粒ｐＢＫ－ＣＭＶ中,转染大肠杆菌ＸＬ１－ｂｌｕｅ,经ＩＰＴＧ诱导后用ＳＤＳ－ＰＡＧＥ分析表达效果。结果 ＲＴ－ＰＣＲ法特异性扩增出日本血吸虫ＧＳＴ编码区基因片段,其     

LDL受体基因cDNA的RT－PCR分离、克隆及其在RFLP中的应用

利用ＲＴ－ＰＣＲ技术分离低密度脂蛋白受体基因ｃＤＮＡ,将长为２６０５ｂｐ的ｃＤＮＡ插入质粒ｐＪＮ６,并经全序列测定证实,该序列与已报道序列相比,存在两个变异碱基,即第７５４位Ｃ→Ｔ,和１６５４位的Ｇ→Ａ,这两个变异碱基并不改变编码的氨基酸,利用ＬＤＬ受体基因ｃＤＮＡ中的ＣｌａⅠ片段作为探针,检测到ＬＤＬ受体基因上外显子８的ＳｔｕⅠ位点是个限制性片段长度多态性位点。所克隆的ｃＤＮＡ含有可译框架的全部密码,因此可作为基因表达材料。     

霍乱毒素B亚单位基因（CtxB）的克隆及其表达

从霍乱弧菌中抽提基因组ＤＮＡ,用ＰＣＥＲ方法获取霍乱毒素Ｂ亚单位基因（ＣｔｘＢ）。序列分析结果表明,ＣｔｘＢ基因编码１２４个氨基酸,其中编码６２位Ｔｈｒ的密码子与文献报道有差异。将ＣｔｘＢ基因插入质粒ｐＧＥＸ－４Ｔ－２,构建ｐＧＥＸ－ＣＴＸＢ表达质粒,转化大肠相菌ＢＬ２１（ＤＥ３０,筛选表达菌株ＣＴＸＢ／ＢＬ２１。工程株经ＩＰＴＧ诱导表达,可产生大量的表达蛋白,经ＳＤＳ－ＰＡＧＥ分析,融合蛋白分子     

用PCR扩增和克隆马立克氏病病毒糖蛋白D基因

用ＰＣＲ技术,从ＧＡ株马立克氏病病毒（ＭＤＶ）感染的成纤维细胞（ＧＥＦ）基因组ＤＮＡ中扩增出ＭＤＶ糖蛋白Ｄ（ｇＤ）抗原基因片段的约１３００ｂｐ编码序列,将该ｐｃＲ扩增的产物于ＥｃｏＲＩ和Ｋｐｎｌ位点克隆到ｐＵＣ１８质粒载体中,在以ｄｉｇｏｘｉｇｅｎｉｎ（ｄｉｇ）标记的ｇＤＰＣＲ产物作为探针,进行原位杂交初步筛选到阳性重组质粒克隆,再根据酶切分析筛选到含ＭＤＶｇＤ基因的重组质粒ｐ１８ＭｇＤ。将ｐ１８ＭｇＤ质粒ＤＮＡ用ｄｉｇ标记后,在Ｓｏｕｔｈｅｒｎｂｌｏｔ中,该探针能识别ＭＤＶ基因组ＤＮＡ的ＢａｍＨＩ－Ａ克隆中的Ａ片段ＤＮＡ。酶切位点分析表明,该ｇＤ克隆也和已发表的ＭＤＶ的ＲＢＩＢ株ｇＤ一样,不含有ＥｃｏＲⅠ、ＨｉｎｄⅢ、ＰｓｔⅠ、ＳｍａⅠ、ｐｖｕⅡ等酶切位点。证明该重组质粒是ＭＤＶｇＤ克隆。     

鼻咽癌组织中Epstein—Barr病毒潜伏感染膜蛋白基因片段的克隆及分析

从两例鼻咽癌（ＮＰＣ）病人的活检组织切片中,用ＰＣＲ方法扩增出ＥＢ病毒潜伏感染膜蛋白（ＬＭＰ）基因的Ｅｘｏｎｌ、Ｉｎｔｒｏｌ ＥｘｏｎΠ和ＩｎｔｒｏｎΠ共５００ｂｐ的片段,克隆入载体ｐＧＥＭ－３ｚｆ（＋）′,测定核苷酸序列,其中有一个样品所测序列段与台湾析相似,另一个样品则与Ｂ９５－８极为相似。由此可知。中国陆南方的ＮＰＣ组织中ＥＢＶ－ＬＭＰ基因存在不同的变异。     

霍乱弧菌zot基因的克隆及其在大肠杆菌中的表达

从霍乱疫苗菌中抽提基因组ＤＮＡ,用ＰＣＲ的方法扩增ｚｏｔ基因。序列分析表明,ｚｏｔ基因编码３９９个氨基酸,其中４个氨基酸与文献报道有差异。将ｚｏｔ基因插入含Ｔ７启动子的质粒ｐＥＴ－２８（ａ＋）构建表达质粒ｐＥＴ－ＺＯＴ,转化大肠檑菌ＢＬ２１（ＤＥ３）筛有达菌株ＢＬＺＯＴ。表达菌株经１ｍｍｏｌ／ＬＴ ＩＰＴＧ诱导表达３－５ｈ后,表达大量ＺＯＴ蛋白,并形成包涵体,经ＳＤＳ－ＰＡＧＥ分析重组ＺＯＴ蛋白分     

鼻咽癌组织中Epstein－Barr病毒潜伏感染膜蛋白基因片段的克隆及分析

从两例鼻咽癌（ＮＰＣ）病人的活检组织切片中,用ＰＣＲ方法扩增出ＥＢ病毒潜伏感染膜蛋白（ＬＭＰ）基因的ＥｘｏｎⅠ、ＩｎｔｒｏｎⅠ、ＥｘｏｎⅡ和ＩｎｔｒｏｎⅡ共５００ｂｐ的片段,克隆入载体ｐＧＥＭ－３ｚｆ（＋）′,测定核苷酸序列,其中有一个样品所测序列段与台湾株相似,另一个样品则与Ｅ９５－８极为相似。由此可知,中国大陆南方的ＮＰＣ组织中ＥＢＶ－ＬＭＰ基因存在不同的变异。     

Recent advances in the study of Kaposi's sarcoma-associated herpesvirus replication and pathogenesis

It has now been over twenty years since a novel herpesviral genome was identified in Kaposi's sarcoma biopsies. Since then, the cumulative research effort by molecular biologists, virologists, clinicians, and epidemiologists alike has led to the extensive characterization of this tumor virus, Kaposi's sarcoma-associated herpesvirus(KSHV; also known as human herpesvirus 8(HHV-8)), and its associated diseases. Here we review the current knowledge of KSHV biology and pathogenesis, with a particular emphasis on new and exciting advances in the field of epigenetics. We also discuss the development and practicality of various cell culture and animal model systems to study KSHV replication and pathogenesis.     

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

正Dear Editor,In December 2019, a novel human coronavirus caused an epidemic of severe pneumonia(Coronavirus Disease 2019,COVID-19) in Wuhan, Hubei, China(Wu et al. 2020; Zhu et al. 2020). So far, this virus has spread to all areas of China and even to other countries. The epidemic has caused 67,102 confirmed infections with 1526 fatal cases     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

Comparative morphology of the carpel in the Liliaceae: Hewardieae, Petrosavieae, and Tricyrteae

The young pistils in the melanthioid tribes, Hewardieae, Petrosavieae and Tricyrteae, are uniformly tricarpellate and syncarpous. They lack raphide idioblasts. All are multiovulate, with bitegmic ovules. The Petrosavieae are marked by the presence of septal glands and incomplete syncarpy. Tepals and stamens adhere to the ovary in the Hewardieae and the Petrosavieae but not in the Tricyrteae. Two vascular bundles occur in the stamens of the Hewartlieae and Tricyrtis latifolia. Ventral bundles in the upper part of the ovary of the Hewardieae are continuous with compound septal bundles and placental bundles in the lower part. Putative ventral bundles occur in the alternate position in the Tricyrteae and putative placental bundles in the opposite. position in the Petrosavieae. The dichtomously branched stigma in each carpel of the Tricyrteae is supplied by a bifurcated dorsal bundle.     

Synthesis and antimicrobial studies of hydrazone derivatives of 4-[3-(2,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid and 4-[3-(3,4-difluorophenyl)-4-formyl-1H-pyrazol-1-yl]benzoic acid

Microbial resistance to antibiotics is an unresolved global concern, which needs urgent and coordinated action. One of the guidelines of the Centers for Disease Control and Preventions (CDC) to combat antibiotic resistance is the development of new antibiotics to treat drug-resistant bacteria. In our effort to find new antibiotics, we report the synthesis and antimicrobial studies of 30 new pyrazole derivatives. These novel molecules have been synthesized by using readily available starting materials and benign reaction conditions. Some of these molecules have shown activity with MIC values as low as 0.78?µg/mL against four bacterial strains; Staphylococcus aureus, methicillin-resistant S. aureus, Bacillus subtilis, and Acinetobacter baumannii. Furthermore, active molecules are non-toxic to mammalian cell line.

     

Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma

Cyclin-dependent kinases (CDKs) and Polo-like kinases (PLKs) play key role in the regulation of the cell cycle. The aim of our study was originally the further development of our recently discovered polo-like kinase 1 (PLK1) inhibitors. A series of new 2,4-disubstituted pyrimidine derivatives were synthesized around the original hit, but their PLK1 inhibitory activity was very poor. However the novel compounds showed nanomolar CDK9 inhibitory activity and very good antiproliferative effect on multiple myeloma cell lines (RPMI-8226).